What risk does Solera’s pay-for-outcomes model shift?

Solera describes its commercial model as “pay for outcomes, not enrollment.” According to the white paper, health plans pay when members reach defined engagement thresholds and clinical outcome benchmarks, with examples including A1c reduction and improvement in pain. Solera concludes that this structure shifts financial risk from the plan to the network.

Some risk is shifted. The more important purchasing question is which risk.

Paying for a milestone reduces one type of risk

Compared with a flat fee paid regardless of whether anyone uses a solution, tying payment to meaningful engagement can protect a purchaser from paying the same amount for members who never meaningfully participate.

Tying another portion of payment to a defined clinical result can move the model one step further: the vendor may receive less compensation when the contracted result is not achieved.

Those are legitimate forms of risk allocation.

But they do not transfer every risk that matters to the purchaser.

A1c improvement, pain reduction, program completion, and meaningful engagement are different outcomes. Each may be clinically valuable. None automatically establishes that the health plan's medical and pharmacy expense fell by more than the amount paid for the intervention.

The pathway remains:

engagement → clinical effect → utilization effect → claims effect → net economic value

A contract can place payment at any point along that pathway. Moving the payment trigger farther downstream may improve alignment, but it does not establish the remaining links.

A contractual outcome is not necessarily an economic outcome

This distinction becomes important when a payment model is described as pay-for-outcomes.

An engagement milestone is primarily evidence that a service was used.

A clinical milestone can provide evidence that the intervention affected a health measure.

A reduction in avoidable utilization moves closer to an economic effect.

A reduction in claims expense net of intervention costs is the purchaser's economic outcome.

These measures should not be treated as interchangeable merely because each can be incorporated into a performance contract.

Eligibility, engagement definitions, clinical performance measures, and payment calculations are separate design decisions. Looser engagement definitions can increase the number of members triggering payment, while tighter eligibility and meaningful-engagement criteria alter both the population being paid for and the population used to measure performance.

The payment model can change the incentive to engage

Solera's model is designed to identify members, direct them toward an appropriate program, and generate engagement. That is operationally sensible. But once engagement or clinical milestones also trigger revenue, the purchaser should understand how targeting and payment interact.

The economic opportunity is not uniform across eligible members.

Some people may have substantial avoidable claims opportunity. Others may benefit clinically from the service but have relatively little probability of generating a measurable reduction in plan-year expense. A payment model can therefore be evidence-informed at the clinical level without being calibrated to the purchaser's incremental economic opportunity.

This creates an important design question:

Does expansion of engagement continue to create purchaser value at the same rate that it creates payable milestones?

The answer may be yes for some populations and no for others.

That is not an argument against engagement. It is an argument for separating the objectives. A purchaser may reasonably buy a program for access, experience, clinical improvement, or other benefits even when near-term medical-cost reduction is not the principal rationale.

The contract should make that decision explicit.

Performance-based payment does not eliminate selection risk

The payment architecture also does not resolve the population problem identified in the Core Review.

If a program disproportionately engages members who are easier to reach, more motivated, lower acuity, or more likely to improve, the contractual performance measures may look favorable even when the population with the greatest medical-cost opportunity remains less engaged.

Performance-contracting therefore places significant weight on defining the eligible population, meaningful engagement, transparent performance metrics, data-sharing requirements, and the ability to verify who is being reached.

For higher-cost populations, purchasers can review historical claims or claims-based target lists to verify that engagement is reaching members with meaningful economic opportunity rather than measuring engagement in isolation.

That principle is directly relevant to a network whose value proposition depends partly on matching the right member to the right level of intervention.

A different first-contract approach

There is another way to allocate early-stage risk.

A purchaser can first underwrite the population and establish a fixed economic budget for the solution, then use the initial contract period to determine whether the vendor can reproduce the proposed operating mechanism:

identify the intended population → reach the appropriate members → match them correctly → generate meaningful engagement → produce the expected clinical and utilization signals → measure those effects reliably

Under that approach, the first contract is not designed to prove value by attaching payment to a collection of intermediate milestones.

It is designed to establish whether the mechanism can be reproduced and measured in the purchaser's population.

Once that operating evidence exists, a subsequent performance-based arrangement can place compensation against measures for which the purchaser has a better empirical understanding of the relationship between the milestone and economic value.

This does not make a fixed-fee contract inherently superior. It separates price underwriting from performance measurement until the purchaser has enough operational evidence to combine them intelligently.

What should a purchaser ask?

Before concluding that a pay-for-outcomes arrangement shifts financial risk, a purchaser should ask:

• What specific event triggers each payment?

• Is the trigger engagement, clinical improvement, utilization change, or economic performance?

• What evidence connects each payable milestone to downstream medical-cost opportunity?

• Does the vendor have an economic incentive to increase the number of members meeting payable engagement thresholds?

• How does the payment structure distinguish higher-opportunity members from members with limited near-term claims opportunity?

• Can the purchaser verify targeting, engagement, clinical results, utilization, and payments using its own data?

• What portion of vendor compensation remains dependent on results that matter economically to the purchaser?

• Would an initial fixed-budget arrangement with operational reporting provide better information before introducing performance-based reimbursement?

What risk remains with the purchaser?

Solera's payment model can shift some non-engagement and clinical-performance risk away from a health plan, depending on the precise contractual thresholds.

But the purchaser still retains substantial risk that the wrong population is engaged, a payable clinical improvement does not alter utilization, any utilization change does not produce sufficient claims savings, or the economic benefit does not exceed the complete cost of the program and network.

Performance-based payment can improve alignment. It does not substitute for determining whether the performance being purchased is economically valuable.